Skip to content

Author

Hyma Mandapaka

We have 1 of 4 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Jul 2026

Lazertinib: A Selective EGFR Mutant Inhibitor to Treat Non-Small Cell Lung Cancer.

One of the leading causes of death related to cancer worldwide is non-small cell lung cancer (NSCLC). Epidermal growth factor receptor (EGFR) mutations are one of the most important therapeutic targets. Lazertinib is an irreversible EGFR tyrosine kinase inhibitor (TKI) that is selectively active against EGFR mutations...

Hyma Mandapaka, Surya Kanta De · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.